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Abstract  
Sub-micron sized silica nanoparticles, even as small as 10-20 nm in diameter, are well known for their 
activation of mononuclear phagocytes. In contrast, the cellular impact of those < 10 nm (i.e., ultrasmall 
silica nanoparticles (USSN)) is not well established for any cell type despite anticipated human exposure. 
Here, we synthesized discrete populations of USSN, with volume median diameters between 1.8 to 16 nm, 
and investigated their impact on the mixed cell population of human primary peripheral mononuclear cells.  
USSN of 1.8-7.6 nm diameter, optimally 3.6-5.1 nm diameter, induced dose-dependent CD4 and CD8 T 
cell activation in terms of cell surface CD25 and CD69 upregulation at concentrations above  ȝ0
SiTOTAL (~500 nM particles). Induced activation with only ~2.4 ȝ0 particles was (a) equivalent to that 
observed with typical positive control levels of Staphylococcal enterotoxin B (SEB) and (b) evident in 
antigen presenting cell-deplete cultures as well as in a pure T cell line (Jurkat) culture. In the primary mixed 
cell population, USSN induced IFN-Ȗsecretion but failed to induce T cell proliferation or secretion of IL-
2, IL-10, or IL-4. Collectively, these data indicate that USSN initiate activation, with Th1-polarisation, of 
T cells via direct particle-cell interaction. Finally, similarly sized iron hydroxide particles did not induce 
expression of T cell activation markers, indicating some selectivity of the ultrasmall particle type.  Given 
that humans may be exposed to ultrasmall particles, and that these materials have emerging bio-clinical 
applications, their off-target immunomodulatory effects via direct T cell activation should be carefully 
considered. 
Table of Contents graphic:  
Keywords: T cells, activation, ultrasmall, silica, nanoparticles, CD25, CD69  
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Nanoparticles that are 1-10 nm in diameter are termed ultrasmall and are attracting significant attention for 
clinical applications.1-4 They have desirable optical, magnetic and quantum confinement properties as well 
as the ability to distribute widely in tissue.5 Ultrasmall silica nanoparticles (USSN) are of particular interest 
due to their tailorable properties and biocompatibility.5 Whilst functionalized USSN are being developed 
for bio-clinical applications, currently most human exposure is likely to be to non-functionalized silica 
nanoparticles. For example, the average UK adult ingests 35 mg silicate particles daily in the form of 
excipients and food additives and, although these are predominately >200 nm in diameter, studies have 
suggested that primary particles of silica  <10 nm can be released during the digestion process.6,7 Exposure 
to amorphous silicates via the lungs is also frequent, in the form of environmental dusts or personal hygiene 
products such as dry shampoo, and other sources such as toners and varnishes.8,9 The impact of inhaled 
amorphous silica and whether it further fractionates, as appears to be the case in the gut, is not well 
understood.10 
The interaction of silica particles of 10-1000 nm diameter with mammalian cells has been extensively 
studied.11 In addition to inducing phagocytic inflammation,12,13 silica nanoparticles have been shown to 
enhance adaptive immunity by increasing cross presentation of co-administered protein antigen by antigen 
presenting cells, and they also act synergistically with bacterial constituents to enhance T cell responses.14-
16
 Humoral immunity has also been found to increase with silica exposure, as SNP-treated animals show 
greater immunoglobulin responses to co-administered protein antigen compared to the non-silica-treated 
controls.17,18 Although such cellular responses to silica particles are established, the impact of the much 
smaller fraction (i.e., USSN) remains unknown in spite of potential human exposure and emerging clinical 
applications.7,19 Here, we investigated the response of primary human peripheral blood mononuclear cells 
(PBMC) to a range of sub-10 nm diameter amorphous silica particles plus a 16 nm silica comparator (i.e., 
non-USSN), all synthesized through size-selective aqueous methods.  
Results/Discussion 
Characterization of USSN dispersions 
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USSN dispersions were generated through the precipitation of orthosilicic acid (Si(OH)4). Orthosilicic acid 
exhibits significantly reduced solubility below pH 9 and, when concentration, pH and ionic strength are 
carefully controlled, it self-associates to form USSN that are metastable under physiological conditions.20 
A dispersion with a median particle diameter of 3.6 r 0.5 nm was prepared by pH-neutralizing an alkaline 
silicate solution of ca. 23 mM Si and incubating it at room temperature for 12-24 h (Figure 1a).  
Silicon-29 NMR spectroscopy was used to determine the extent of silicate condensation for an identical 
USSN dispersion prepared from 29Si-enriched (99.35 atom%) materials (Figure 1b, Table 1). Amorphous 
silica, whose long-range formula is SiO2, consists of tetraoxosilicon centres (denoted Q for 
quadrifunctional) interlinked by siloxane bonds.21 A fully condensed Si centre (Q4, being linked to 4 other 
centres) can only exist in the core of a particle, whereas partially condensed centres (Q2 or Q3) are associated 
with the surface. USSN accounted for most (84 r 3%) of the silicon content in the dispersion and, of this, 
43% was partially condensed (Q2 & Q3) and 57% was fully condensed (Q4). The remaining Si content was 
comprised of aqueous monomeric (Q0) and dimeric (Q1-Q1) silicic acid molecules.22-24 
Table 1. Silicon distribution in the dispersion, as determined by integration of the 29Si NMR 
spectrum; Qn represents a Si atom with n FRRUGLQDWHGí26LJURXSV 
Overall Si distribution USSN Si distribution 
Q0, Q1 
(dissolved) 
Q2, Q3, Q4 
(USSN) 
Q2, Q3 
(surface) 
Q4  
(core) 
16 ± 3% 84 ± 3% 43 ± 2% 57 ± 2% 
 
A significant fraction of the terminal hydroxyl groups (residing at partially condensed Si centres) on USSN 
is deprotonated at physiological pH, as evidenced by 8661¶V negative zeta-potential both in the stock 
dispersion at pH 7.1 (Figure 1c) and in the more complex media, namely PBS and RPMI (Table S1). 
Inexorably, therefore, any USSN encountered by cells would be negatively charged.  
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USSN with a median hydrodynamic diameter of 3.6 r 0.5 nm were calculated to contain 330 ± 62 Si atoms, 
assuming a hydration shell of 0.2-0.6 nm and an amorphous silica density of 1.90 g/cm3.25 This Si packing 
density is in agreement with that obtained by manual addition of small energy-minimized silica clusters26 
to construct a 2.9 nm hydration shell-deficient particle (Figure S1) and also with values reported in the 
literature (22-29 Q4 centres/nm3).27 Based on these data, and the NMR analyses above, a dispersion of 3.6 
nm USSN at
 
1 mM SiTOTAL approximates to a 3 ȝ0 particle concentration. 
 
Figure 1. Physical characterization of USSN. a. Particle size distribution of a USSN dispersion (ca. 23 
mM Si, pH 7, incubated 15 h) b. Silicon-29 NMR spectrum of an equivalent USSN dispersion that is 
enriched 99.35 atom% in 29Si. The signal corresponding to orthosilicic acid (Q0) is set to 0 ppm. c. pH-
dependence of USSN zeta-potential in UHP water (mean ± SD).  
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Cellular responses to USSN dispersions 
The effect of USSN on PBMC viability was investigated. USSN of 3.6 ± 0.5 nm median diameter were 
added to tissue culture media at 150- ȝ0 SiTOTAL (ca. 0.5-2.4 ȝ0 particles) and the viability of 
monocyte, B and T lymphocyte cell subsets was examined after 24 h incubation. The percentage of viable 
monocytes and B cells decreased in a dose-dependent fashion, with significant reduction being evident at 
ȝ0SiTOTAL (Figure 2). The viability of T cells also decreased, although their tolerance to USSN was 
greater than that of B cells or monocytes, possibly due to differences in particle uptake and intracellular 
loading.12,28 Orthosilicic acid, over the same SiTOTAL concentration range, had no effect on cell viability 
(data not shown).  
Having established sub-lethal concentrations of USSN, we next examined transcriptional responses of 
3%0&V WR WKH SDUWLFOHV DW  ȝ0 SiTOTAL). Consistent with established pro-inflammatory responses 
towards larger silica particles,12,13 multiple gene groups that are associated with inflammation were 
upregulated in response to USSN (Tables S2 and S3) ± including latent infection of homo sapiens with 
Mycobacterium tuberculosis (30 genes), P75NTR signals via 1)ț%JHQHV.(**UKHXPDWRLGDUWKULWLV
(86 genes) and WP530 cytokines and inflammatory response (23 genes). Indeed, modest inflammasome 
activation by USSN was confirmed through LPS priming of PBMC and then chasing with USSN at three 
concentrations. USSN enhanced IL-1ȕ protein secretion beyond vehicle alone, corroborating previous 
studies with larger particles,15 albeit not to the same extent as the positive control (insoluble peptidoglycan 
from Staphylococcus aureus: Figure S2).29 
Immune CEll POPulation analyses (ICEPOP), as developed by Wijaya et al. to identify responding cell 
types in mixed cell cultures,30,31 revealed that classical phagocytic cells (dendritic cells and especially 
monocytes) were the subtypes most significantly affected by USSN (Figure 2b and Table 2). These cells 
are well known to respond to SNP > 10 nm diameter,12,15 and hence our data demonstrate that phagocyte 
responsiveness also extends to USSN despite the small particles size. It is likely that these cells have other 
endocytic uptake mechanisms in addition to classical phagocytosis of larger particles. For natural killer 
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(NK) cells a lesser but still significant response was also observed when the mixed cell culture was 
challenged with USSN (Figure 2b and Table 2). However, these cells respond non-specifically to danger 
signals,32,33 and typically to inflammatory signalling, just as we observed here for the PBMC challenge with 
USSN (see above). For B cells, the responses of all gene groups barely rose above the threshold for 
significance when the PBMC were exposed to USSN (Figure 2b). At the single gene level, however, two 
B cell-specific genes were significantly up-regulated (Table 2), consistent with B cells having 
endocytic/phagocytic capability and with the known effect of larger SNP in enhancing B cell antigen 
responses.17,18 Finally, T cells, which are not known to take up particles or to respond non-specifically to 
danger signals,12,38 demonstrated an unanticipated reaction to USSN challenge. In particular, the response 
of gene groups associated with 12 hour activated Th1 T cells and with memory T cells (resting and activated) 
were clearly enhanced above the no response cell threshold (Figure 2b). Two genes, which the ICEPOP 
algorithm considers specific to T cells (ICOS, ZBED2),34 were upregulated by USSN. Other genes with an 
expression typically associated with T cells, albeit not entirely specifically so, were also upregulated by 
USSN. For example, genes which commonly correspond to T cell signalling (ly9) as well as to activation 
of cytotoxic and helper T cells (CRTAM, CD69, IFN-Ȗ ;&/) had increased expression after USSN 
treatment.35-37  
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Figure 2. The cellular activity of USSN on primary peripheral cells. a. The effect of USSN on monocyte 
(CD11c), B cell (CD19) and T cell (CD3) viability in PBMC culture at 24 h. (* denotes significance 
compared to the control, two-tailed paired T-test, p < 0.05, n = 4-18.) b. Response of specific cell subtypes 
to ȝ08661 as identified using Immune CEll POPulation (ICEPOP) analysis of gene expression data 
(n=3). Values above the cell type response threshold (CR) indicate cell subtype responders and the length 
of the histogram (ICEPOP score) denotes the extent of this response. 
 
Table 2. The up-regulatory HIIHFWRIȝ08661 on the expression of genes associated specifically with 
monocytes, dendritic cells, B cells, NK cells and T cells; genes were identified by Abbas et al.34 
Cell type Up-regulated genes 
Monocyte 
CCRL2, CTSD, CTSL, CXCL5, DFNA5, GJB2, 
GPR84, IL1RN, IL24, MMP19, NPC1, NRIP3, 
PLAUR, PLD1, SNX9, ZFYVE16 
Dendritic cells CHST7, NR4A3, RAB9A, TTYH2 
B cells EIF2AK3, ELL2 
NK cells TGFBR1 
T cells ICOS, ZBED2 
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These findings raised the possibility that USSN could activate T cells. We therefore sought confirmation at 
the protein level using cell membrane markers of T cell activation. CD25 is a component of the IL-2 
receptor and is involved in late-stage T cell proliferation and differentiation.39,40 CD69 is an earlier and 
more sensitive marker of T cell activation, and is involved in cytotoxic function as well as in T cell 
migration and retention.35,41,42 USSN, at 150- ȝ0 SiTOTAL (ca. 0.5-2.4 ȝ0 particles), significantly 
induced both cell surface markers on primary human CD4 and CD8 T cells of PBMCs in a dose-dependent 
fashion. At the highest USSN dose, the effects were equivalent to those LQGXFHGE\W\SLFDOµSRVLWLYHFRQWURO¶
levels of superantigen Staphylococcal enterotoxin B (SEB), both in terms of percentage positive cells 
(Figure 3a-3b) and fluorescence intensity (Figure 3c-3d). Non-particulate silica (i.e., orthosilicic acid) at 
the same concentrations had no effect. USSN determinants of T cell viability and T cell activation appeared 
to be unrelated. At  ȝ0 SiTOTAL, for example, there was significantly increased expression and 
fluorescence intensity of CD69 on CD4 and CD8 T cells, as well as enhanced fluorescence intensity of 
CD25 on CD8 T cells, whereas viability of these cells was unaffected. Moreover, USSN-induced 
upregulation of CD25/69 followed a dose-dependent sigmoidal curve (r2 = 0.686-0.882, Figure 3a-d). 
USSN-induced T cell death was not dose-dependent (r2 = 0.18, Figure 2a), by contrast. 
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Figure 3. The cellular activity of USSN on primary T cells. The effect of SEB, orthosilicic acid (Si(OH)4) 
and USSN on the percentage of CD4 (a.) and CD8 (b.) T cells that are positive for CD25 and CD69 in 
PBMC culture after 24 h. The effect of SEB, orthosilicic acid and USSN on the mean fluorescence intensity 
(MFI) of CD25 and CD69 on CD4 (c.) and CD8 (d.) T cells in PBMC culture after 24 h. Data shown 
represent the mean ± standard deviation for 7 donors. (* denotes significance compared to the control, 
two-tailed paired T-test, p < 0.05.) Representative bivariate dot plots show expression of CD25 and CD69 
on CD4 (e.) and CD8 (f.) T cells. The percentage of cells positive for CD25 and CD69 followed a dose-
dependent sigmoidal curve (r2 = 0.75 and 0.88, respectively, for CD4 T cells and 0.72 and 0.69, respectively, 
for CD8 cells). 
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We next investigated whether CD4 or CD8 T cells proliferated in response to USSN. In marked contrast to 
the SEB positive control, USSN, induced minimal proliferation of either CD4 or CD8 T cells following 3 
or 5 days of culture (Figure 4a-d) at levels that stimulated high T cell expression of CD69 and CD25. In 
corroboration, IL-2, a cytokine essentially involved in late-stage T cell proliferation, was significantly 
secreted at days 1, 3 and 5 by cells challenged with SEB but was only present at, or close to, baseline levels 
in the supernatants of cells exposed to USSN (Figure 5a). 
Thus, USSN induced markers of T cell activation, but only minimal proliferation. Next, therefore, by 
measuring classical T cell-derived cytokines from PBMC challenged with USSN, we considered the 
possible role of these activated-but-non-proliferating T cells in the development of T helper cell responses 
by assessing cytokine levels associated with regulation (IL-10), Th1 (IFN-ȖRU7K2 (IL-4) phenotypes.43,44 
Positive control SEB induced all three cytokines, but IFN-Ȗ secretion was dominant. USSN failed to 
stimulate IL-4 and IL-10, but induced IFN-Ȗ in a dose-responding fashion despite the lack of T cell 
proliferation (Figure 5b-d).   
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Figure 4. The impact of USSN on primary T cell proliferation. The effect of SEB and USSN on the 
percentage of divided (CFSE dilute) CD4 (a.) and CD8 (b.) T cells in PBMC culture after 3 d and 5 d. Data 
shown represent the mean ± standard deviation for 7 donors (p-values show differences compared to the 
control, two-tailed paired T-tests). Representative bivariate dot plots show CFSE intensity of CD4 (c.) and 
CD8 (d.) T cells 
 
13 
 
 
Figure 5. The impact of USSN on cytokine levels in supernatants of primary PBMC cultures. The 
effect of SEB and USSN on IL-2 (a.), IFN-Ȗ (b.), IL-4 (c.) and IL-10 (d.) levels in PBMC culture 
supernatants. IL-2 levels were assessed after 1 d, 3 d and 5 d incubations. IFN-Ȗ,/-4 and IL-10 levels were 
assessed after 1 d incubation.  Data shown represent the mean ± standard deviation for  5 donors. (* 
denotes significance compared to the control, two-tailed paired T-test, p < 0.05.)  
 
Next we considered whether USSN size was critical for initiation of T cell activation. Most nanoparticles 
are unstable in complex media, readily interacting with protein and/or forming aggregates.45,46 Additionally, 
USSN will dissolve when diluted below the solubility limit of silicic acid (ca. 1.7 mM Si).21 Ultrafiltration 
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and elemental analysis (Figure 6a and S3) revealed that, indeed, the phase distribution of the 3.6 nm USSN 
stock dispersion changed after GLOXWLRQWRȝ0SiTOTAL in tissue culture medium. Within 30 minutes of 
dilution, ca. 25% of the particles had agglomerated (into clusters with a diameter greater than 11 nm) and 
ca. 35% had dissolved (Figure 6a). The large agglomerated fraction was unchanged after an hour, but 
percent dissolution had increased. Finally, by 8 h, nearly all the USSN had dissolved (Figure S3). These 
results imply that (a) USSN would have relatively short-lived encounters with cells, and (b) the size 
responsible for inducing T cell activation is uncertain. We therefore generated five stock suspensions with 
narrow size distributions and median diameters ranging from 1.8 ± 0.7 to 16 ± 1.3 nm (Figure 6b), using 
pH, Si concentration and salinity to tailor particle growth (see Methods). After 24 h exposure, only the 16 
nm particles failed to elicit T cell activation in PBMC cultures, whereas all ultrasmall particles were 
effective; optimal activation, adjudged by CD25 and CD69 expression, occurred with USSN of 3.6-5.1 nm 
diameter (Figure 6c,d). Dissolution over time in simple aqueous media, mimicking that in cell culture, 
indicated that cell encounters with USSN of 1.8 ± 0.7 nm diameter would be much briefer than those 
involving larger particles (Figure 6e), which would suggest that the decreased efficacy of the smallest 
particles could be due to their size, short lifetime, or both. Given the differing dissolution profiles of the 
dispersions, the overlap in size distribution as measured in the stock solutions, and the alterations to particle 
size in complex media, the exact identity of the µRQ-WDUJHW¶ particle size(s) responsible for cell activation is 
not known. Notwithstanding, our results demonstrate that only silica nanoparticles that start out in the 
ultrasmall size range (i.e., < 10 nm in diameter) are capable of inducing significant T cell activation and, 
with our methods of particle preparation, optimally so at 3.6-5.1 nm.  
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Figure 6. Size-dependent properties of the USSN dispersions and their effect on induced T cell 
activation. a. Percentage of silicon that passed through 3 and/or 1,000 kDa ultrafilters in USSN dispersions 
(ca. P0S+KDQGDIWHUGLOXWLRQWRȝ06LDQGLQFXEDWLRQDW °C in RPMI + 10% FBS media 
for 0-1 h. b. Particle size distribution for tailored USSN dispersions (20-40 mM Si), mainly through 
differential saline addition, after 24 h incubation at room temperature. c-d. Expression of CD25 and CD69 
on CD4 and CD8 T cells in PBMC cultures treated with USSN dispersions of different particle sizes after 
24 h. Data shown represent the means ± standard deviation for a minimum of 8 donors. Lines denote a 
statistically significant difference (2-way ANOVA, p<0.05). e. Effect of USSN size on dissolution rate after 
dilution to ca. 1 mM Si in HEPES buffer (pH 7.0-7.3) 
 
We next investigated whether USSN induced T cell activation directly or indirectly. Previous studies have 
shown that silica nanoparticles larger than USSN are able to (i) promote cross-presentation of exogenously 
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derived antigen by antigen presenting cells (APCs), thereby enhancing the activity of matched (i.e., antigen-
specific) responder CD8+ T cells,14 and (ii) act synergistically with bacterial-derived components to increase 
T cell activation.15,16 In our experiments, however, bacterial components were lacking, given the normal, 
sterile cell culture environment. Similarly, exogenous antigen and antigen specific T cells were not added, 
and primary peripheral blood T cells are expected to be unresponsive to normal cell culture proteins, as our 
baseline data indicated. We therefore considered scenarios whereby USSN might initiate the activation of 
T cells without additional stimuli. Superantigens activate T cells by, generally, crosslinking the T cell 
receptor (TCR) to MHC class II receptors, as occurs with SEB for example,47 while anti-CD3 and anti-
7&5Įȕ mitogenic antibodies activate T cells by directly engaging the TCR:CD3 complex.48 We probed the 
µFURVV-OLQNLQJ¶ possibility for USSN by reducing the proportion of cells in culture that were positive for 
MHC class II receptors. These receptors are ubiquitous on APCs such as B cells and monocytes, but occur 
on only a minority of T cells (6.01 ± 2.84% of CD3+ T cells) and some NK cells (9.3-37.7%).49,50 We 
therefore depleted PBMCs of monocytes (Figure S4) and first confirmed that this led to a significant 
decrease in the percentage of CD4 T cells positive for CD25 or CD69 after treatment with SEB (30.1 ± 
4.0% (PBMC) versus 18.5 ± 5.1% (monocyte-deplete PBMC) for CD25 and 42.4 ± 5.8% (PBMC) versus 
28.2 ± 4.5% (monocyte-deplete PBMC) for CD69). However, with USSN challenge there was no such 
decrease of these markers on CD4 T cells in monocyte-depleted cultures (21.5 ± 8.6% (PBMC) versus 23.3 
± 6.5% (monocyte-deplete PBMC) for CD25 and 52. 7± 13.4% (PBMC) versus 68.5 ± 12.6% (monocyte-
deplete PBMC) for CD69). Indeed, CD25 and CD69 on CD8 T cells, which are also known to cross-link 
superantigen to MHC class II receptors,47 was significantly higher in the monocyte-depleted cultures 
compared to that in PBMC cultures (p < 0.005, Figure 3b versus Figure 7a). Collectively, this indicated 
that, unlike for SEB, USSN-induced activation of T cells does not require a bridging (i.e., cross-linking) 
cell expressing the MHC class II receptor and may therefore be via direct T cell-particle interaction. To 
confirm this, we investigated the impact of USSN on Jurkat cells, which have a CD4 phenotype and do not 
express MHC class II receptors.51 Despite high basal CD69 levels, exposure to USSN further increased the 
percentage of CD69 positive cells whereas SEB, which cannot be cross-lined and bind the TCR sequence 
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on Jurkat cells,52 had no such effect (Figure 7b). We therefore conclude that USSN activate T cells directly 
and that the presence of other cells, such as APCs, is not necessary and may actually decrease induced 
activation, presumably due to competition for cell surface binding and/or uptake of USSN.  
Finally, we investigated whether non-silica based ultrasmall particles were also capable of inducing T cell 
activation.  Iron hydroxide nanoparticles (IHNP) of 4.4 ± 0.5 nm median diameter (Figure 8c) and a zeta-
potential of -40.0 ± 2.0 mV at pH 6.5 were added at ȝ0IronTOTAL to complete tissue culture medium 
(as used for the USSN work) or to a basic salt solution which minimizes agglomeration of the iron hydroxide 
particles.53 Ultrasmall IHNP did not significantly induce CD25 or CD69 on T cells in either medium, unlike 
USSN (Figure 7d,e). Whether the difference in zeta-potential or surface composition between USSN and 
IHNP is responsible for their differential T cell effects is not clear, but the results indicate that ultrasmall 
nanoparticle-induction of T cell activation is restricted to certain particle types which, at least, includes 
USSN. 
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Figure 7. The lack of requirement of APCs in USSN-induced T cell activation and the lack of effect 
of iron hydroxide nanoparticles on T cell activation. a. The effect of USSN on CD25 and CD69 
expression on T cells in enriched T cell cultures. Data represent the means ± standard deviation for 6 donors. 
(* denotes significance compared to the control, paired T-test, p < 0.05.) b. The effect of USSN on Jurkat 
cell line CD69 expression. Data shown represent the means ± standard deviation for 3 independent 
replicates. (* denotes significant compared to the control, unpaired T-test, p < 0.05.) c. Size of iron 
hydroxide nanoparticles in water versus USSN. d-e. The effect of IHNP and USSN on CD25 and CD69 
expression on CD4 and CD8 T cells in PBMC cultures suspended in TCM and BSS. Data shown represent 
the means ± standard deviation for 8 donors. (* denotes significance compared to the control in the specific 
media, one-way ANOVA, p < 0.05.) 
 
Conclusions  
Ultrasmall nanoparticles of silica are toxic to mononuclear cells, but, additionally and independently, are 
potent inducers of cell surface CD25 and CD69 for both T helper (CD4) and CD8 T cells. Our data suggest 
that the interaction is direct ± between the particle and the T cell ± and does not physically require 
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µLQWHUPHGLDU\¶$3&V to bridge or cross-link the interaction. The relatively broad range in size dependency 
of USSN in T cell activation further supports direct binding: silica particles from 1-2 nm to 7-8 nm in 
diameter, which have particle volumes from ~4.2 nm3 to ~268 nm3, respectively, are unlikely to be capable 
of cross-linking receptors in a similar fashion so a single point interaction is more plausible. Moreover, the 
rigid nature of USSN, unlike organic superantigens, would not readily facilitate cross-linking interactions. 
In addition to these findings, USSN induced significant secretion of IFN-Ȗ in PBMCs. IFN-Ȗ stimulates 
increased MHC Class I and Class II expression, antigen presentation and cytokine secretion by APCs, as 
well as killing by NK cells and neutrophils and the further skewing towards a Th1 inflammatory T cell 
phenotype. As such, it is widely considered to be a key mediator of cellular immune responses by initiating 
multiple factors supporting cellular immunity.44,54,55  
The T cell stimulatory effect in our work was restricted to USSN, as ultrasmall iron hydroxide nanoparticles 
did not activate T cells. However, zinc oxide nanoparticles, cobalt nanoparticles and fullerenes have all 
been shown to induce IFN-ȖSURGXFWLRQ,56-58 so the potential for other ultrasmall nanomaterials to influence 
T cell responses should not be ignored, especially given known exposure.59,60 Notwithstanding, the USSN 
effect appears potent presumably because the particles do not completely agglomerate in complex medium 
and have a local surface geometry/Si-OH affinity for binding. T cells are not known for particle uptake but 
particles have been shown to interact with these cells via cell surface adhesion.28 Whether the T cell 
activation effect is non-selective or involves specific receptors deserves further scrutiny.  
Human exposure levels to USSN have not yet been quantified. However, as noted above, these ultrasmall 
particles are expected to fractionate from the oral additive/excipient E551 in the digestive process,7 which 
could allow for interactions with the luminally-exposed, intestinal intra-epithelial T cells, as occurs with 
orally delivered anti-CD3 antibodies.61,62 Biomedical applications, including bioimaging, are another 
potential exposure to USSN.2,5 The impact of USSN exposure on immune cell activation in vivo via T cell 
interactions merits consideration. 
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Methods/Experimental  
USSN dispersion preparation and characterization 
Preparation. Amorphous silica nanoparticle dispersions were prepared by diluting aliquots of a concentrated 
alkaline sodium silicate solution (#338443; Sigma-Aldrich Chemical Co., Gillingham, UK) to 23 mM Si in 
ultra-KLJKSXULW\ZDWHU0ȍFPDQGDGMXVWLQJWRS+ZLWK0HCl. This method produced dispersions 
of USSN with 3.6 ± 0.5 nm median diameter. To produce dispersions with median diameters of 5.1 ± 0.6 
and 7.8 ± 0.7 nm, saline (1.5 M stock) was added at a concentration of 30 and 154 mM NaCl, respectively, 
immediately after pH adjustment. Dispersions with a median diameter of 16 ± 1.3 nm were prepared by 
adjusting an alkaline silicate solution at 40 mM Si to pH 7 with 4 M HCl. Dispersions of smaller particles 
(mean diameter < 2 nm) were prepared by rapidly dropping the pH of an alkaline silicate solution, at 500 
mM Si, to 0.9 with concentrated HCl (37%) in the presence of a sucrose stabilizer.63 These low pH 
dispersions were neutralized immediately prior to use. All dispersions were aged at room temperature for 
12-24 h and analyzed by dynamic light scattering prior to use.  
Particle size. Hydrodynamic particle size was determined at room temperature by dynamic light scattering 
using a Zetasizer NanoZS or NanoZSP (Malvern Instruments, Malvern, UK). Acquisition parameters for 
silicon dioxide for USSN (refractive index = 1.45, absorption = 0.01) and bernate for iron hydroxide 
nanoparticles (refractive index = 1.92, absorption = 0.10) in a water matrix (1.0031 cP, refractive index = 
1.33) were used, along with a 173° backscatter angle. For each sample, three replicate measurements were 
recorded and the average volume particle distribution reported as DV0.5, corresponding to the 50% 
cumulative undersize particle distribution. Zeta-potential of the USSN was determined with the NanoZSP, 
D FDSLOODU\ FHOO FXYHWWH '76 DQG WKH 6PROXFKRZVNL GLIIXVLRQ PRGHO ZLWK )țD    8661
dispersions were pH adjusted from 1.5 to 9, or diluted in PBS or RPMI, immediately prior to zeta-potential 
analysis. For each dispersion, zeta-potential measurements were carried out on three independent 
preparations, with 3 replicate measurements per preparation. 
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Dissolution in simple media. USSN persistence under physiological conditions was assessed using a 
molybdic acid dissolution assay.64 Orthosilicic acid, but not polymeric silica, is complexed by molybdic 
DFLGWRIRUPDȕ-silicomolybdate complex that absorbs at 400-450 nm. Following dilution to 1 mM Si in 
+(3(6EXIIHUS+8661GLVVROXWLRQZDVDVVHVVHGE\DGGLQJȝ/PRO\EGLFDFLGUHDJHQW
mM (NH4)6Mo7O24 ·  4H2O in 0.15 M H2SO4WRȝ/RIWKHGLOXWHGVDPSOHLQDZHOOSODWH$IWHU
min incubation at room temperature, the absorbance at 405 nm was measured on a Labsystems Multiskan 
RC V1.5-0 plate reader (ThermoScientific, UK). A calibration curve was similarly generated by diluting 
aliquots of SiF4 silicon standard (1,000 mg/kg Si; Sigma-Aldrich Co) in HEPES buffer.  
Particle size and solubility in TCM. The particle size and solubility of USSN were also determined in 
complex media. Dispersions were passed through 3 or 1,000 kDa MWCO centrifugal ultrafilters (Vivaspin-
500, Sartorius Stedim Biotech; 13,000 rpm for 10 min), which have nominal pore sizes of 1-2 or 11 nm, 
respectively.65 Total Si analysis (see below) thus revealed the percentages in the dispersion below 1-2 nm 
(considered soluble), between 1 and 11 nm, and above 11 nm in size. 
Total Si analysis of dispersions and their particle-sizing fractions was conducted by inductively coupled 
plasma - optical emission spectroscopy (ICP-OES) at 251.611 nm on a Jobin Horiba Ultima 2C with a V-
groove nebulizer (Instrument SA, Longjumeau, France), using a flow rate of 0.83 mL/min. Samples were 
diluted with a pH 10 NaOH solution prior to analysis. Calibration solutions (0.2-70 ppm) were similarly 
prepared from a SiF4 silicon standard (Sigma-Aldrich Chemical Co). 
29Si NMR spectroscopy was used to characterize USSN dispersions that were prepared as described above 
except from isotopically-enriched potassium silicate solutions obtained by dissolving 29SiO2 (Isonics, 99.35 
atom% 29Si) in an aqueous KOH solution at 170 °C for 24 h in a PTFE-lined pressure vessel. Spectra were 
acquired at 25 °C on a Bruker AMX500 spectrometer (99.35 MHz) with an Si-free probe and 10 mm O.D. 
Kel-)VDPSOHWXEHHPSOR\LQJʌSXOVHVDQGDVLQWHUSXOVHSHULRG 
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Iron hydroxide nanoparticles synthesis. Iron hydroxide nanoparticles coated with adipate and tartrate were 
prepared as described previously.66 Briefly, the pH of an acidic solution containing iron (III) chloride and 
organic acids was increased to pH 7.4 with NaOH while agitating. The dispersion was dried at 40 °C and, 
prior to cellular experiments, the iron hydroxide nanoparticles were dispersed in a stock dispersion at 40 
mM Fe and particle size was measured by DLS. 
Theoretical modelling 
Supplementary Fig 1 was created by aggregating a primary (SiO2)24 cluster, which had been previously 
DFT optimized in a hydrated environment.25 The smaller clusters were aggregated by eye and allowed to 
relax locally using the Monte-Carlo algorithm in CrystalMaker®.67 Further relaxation was not performed. 
The cluster size was determined from extrapolation of the composition of the previous (SiO2)24 cluster, 
assuming a continuous surface width of 2.8 Å, which was determined from the average distance from a 
surface (unterminated) oxygen atom to the first fully condensed (Q4) silicon atom. 
Cellular studies 
Cell culture. The Jurkat T cell line was acquired from Leibniz-Institut DSMZ-Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH. Cells were maintained in Roswell Park Memorial Institute 
(RPMI)-1640 media containing 10% fetal bovine serum (FBS), 0.3 g/L L-glutamine, 1% penicillin-
streptomycin (all from Sigma-Aldrich Co). 
Human peripheral blood mononuclear cells (PBMC) were isolated from fresh single leukocyte cones 
(National Blood Service, Cambridge, UK) using density gradient centrifugation. Isolated cells were rested 
for 2 h and either used as is or stored in freezing medium (10% dimethyl sulfoxide, 50% FBS, 40% RPMI 
1640) at -80 °C or in N2(l). Frozen cells were rapidly thawed, washed, and then rested for 2 h before use in 
RPMI containing 10% FBS, 0.3 g/L L-glutamine, 1% penicillin-streptomycin and 0.01 µg/mL DNase.  The 
enrichment of T cells through monocyte adherence was conducted by adding PBMC cultures (1-2 × 106 
cells/mL) to a 6 well plate and incubating at 37 °C for >1 h. Non-adherent cells were transferred to a fresh 
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6 well plate and adherent cells were discarded. After repeating 3 times, cells were counted and enrichment 
was assessed using flow cytometry. T cell enrichment was also conducted using a pan T cell negative 
isolation kit (MACS Miltenyl Biotec, #130-096- DFFRUGLQJ WR PDQXIDFWXUHU¶V VSHFLILFDWLRQV $IWHU
enrichment, T cells were rested for a minimum of 2 h prior to use. Difference in activation induced in 
PBMC and enriched T cell cultures was calculated by: (%CDXXEN T cells - %CDXXPBMC)/ %CDXXPBMC x 
100%. 
Human PBMC assays were approved by the University of Cambridge Human Biology Research Ethics 
Committee (ref. HBREC.2015.10) 
Cell treatments. Treatments were prepared immediately prior to testing. USSN dispersions were prepared 
as described above and sterile filtered (0.2 µm) prior to addition to RPMI media (#R0883, Sigma-Aldrich 
Co.). RPMI supplemented with silicic acid was prepared by diluting sodium silicate solution into RPMI, 
mixing for 5-30 minutes (spiral mixer) and neutralizing with HCl immediately prior to testing. 
Staphylococcal enterotoxin B (SEB, Sigma Aldrich, #S4881) in RPMI media containing FBS (#F9665, 
Sigma-Aldrich Co.) was employed as a positive control. Cells suspended in FBS-containing RPMI were 
subjected to USSN or SEB for 24 h, 48 h or 72 h and then both the cells and medium were collected (for 
flow cytometric analysis and for ,)1Ȗ, IL-10, IL-2 and IL-4 analyses, respectively). For assessing IL-ȕ
levels (via ELISA), cells were rested for 3 h or pre-stimulated with 10 ng/mL lipopolysaccharide. The cells 
were washed and subjected to USSN or SEB for 3 h. Cultures were washed again, resuspended in TCM, 
and incubated for another 21 h. Insoluble peptidoglycan from Staphylococcus aureus was used as the 
positive control.29 Media were collected for the IL-ȕDQDO\VLV  
Basic Salt Solution (BSS) was prepared as previously described53 and was comprised of 3.04 g/L 
piperazine-11ƍ-bis(2-ethanesulfonic acid) (PIPES), 7.60 g/L NaCl, 70.74 g/L KCl, 0.12 g/L MgSO4, 0.90 
g/L glucose and 0.24 g/L CaCl2 at pH 6.5. 
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Gene array. PBMC cultures were treated with 15ȝ0USSN and incubated for 4 h. RNA was collected 
XVLQJDQ51HDV\0LQLNLW4LDJHQDFFRUGLQJWRPDQXIDFWXUHU¶VVXJJHVWHGSURWRFRO and was stored 
at -80 °C until analysis. Differences in expression were calculated using an R package limma based on the 
log2 intensities (fold change = averagedonorsA-C(2log2(USSN) ± log2(control)). Gene array were data published on the 
GEO repository, accession number GSE113088.  Mean fold changes were uploaded to the ICEPOP 
software,29 selecting species (human), fold change threshold (1.5), and the number of random samples 
(100). Cell population response was plotted by subtype data. 
Flow cytometry. Cell proliferation was assessed using a carboxyfluorescein diacetate, succinimidyl ester 
(CFDA-SE, 90%, Sigma-Aldrich Chemical Co., UK) dilution assay, as previously described.68 Cells were 
VWDLQHGZLWKȝ0&)'$-SE at 106 cells/mL for 7 min prior to treatment with USSN. Cells were stained 
ZLWKIOXRUHVFHQWDQWLERGLHVDFFRUGLQJWRWKHPDQXIDFWXUHU¶VVXJJHVWHGSURWRFROZLth minor changes. Surface 
DQWLERG\VWDLQLQJZDVFRQGXFWHGE\DGGLQJDIOXRUHVFHQWDQWLERG\FRFNWDLOWRFHOOVLQȝ/3%6
BSA and incubating on ice for 20 min. For the Invitrogen viability marker, cells were pre-stained with the 
viability dye for 20 min on ice and washed prior to surface staining. For the 7-AAD viability marker, the 
viability stain was added to the cells after surface antibody staining and cells were incubated at room 
temperature for 10 min. Antibodies and stains used were CD3-VioGreen (Miltenyi Biotec, #130-096-910), 
CD3-PE (BD Pharmingen, #555340), CD4-PE (BD Pharmingen, #555347), CD8-APC-Cy7 (BD 
Pharmingen, #557834), CD25-FITC (BD Pharmingen, #555431), CD69-APC (BD Pharmingen, #555533), 
CD11c-APC (BD Pharmingen, #559877), CD19-APC-Cy7 (BD Pharmingen, #557791), 7-AAD (Life 
technologies, #A1310, Biolegend, #420404), and LIVE/DEADTM Fixable Violet Dead Cell Stain Kit 
(Invitrogen, #L34955). All cells were washed and then fixed with PBS + 2% paraformaldehyde. Single 
stained compensation tubes were prepared alongside the fully stained samples. Flow cytometry analyses 
were conducted immediately thereafter using a Beckman Coulter CYAN ADP flow cytometer, equipped 
with 405, 488 and 642 nm solid-state lasers and 11 detectors in standard configuration. Beckman Coulter 
Summit software was used for data acquisition and analysis. The cytometer was calibrated with alignment 
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beads (Spherotech, USA), and the coefficients of variation for each channel was within the range set by the 
manufacturer. 400,000 events or the complete suspensions were acquired. All samples were filtered through 
35 µM nylon mesh filters immediately prior to analysis. Flow cytometric data files were saved without 
applying compensation. Spectral overlap was assessed and data analyzed with the use of unstained and 
single stained compensation cell samples (1 for each fluorophore used). Compensation was applied 
according to single stains during post-acquisition analysis to minimize spectral overlap using Summit V4.3 
software (Beckman Coulter, UK). For flow cytometric data analysis, treated cells were assessed against the 
untreated control. An example of the gating strategies used can be found in Figures S5-S7. 
ELISA. Cytokine analysis was conducted on the cell supernatants using IL-2 (#DY202), IL-4 (#DY204), 
IL-10 (#DY217B), IFN-Ȗ'<DQG,/-ȕ'<(/,6$NLWVDOODFTXLUHGIURP5	'6\VWHPV
according to PDQXIDFWXUHU¶VVSHFLILFDWLRQV.  
Statistical analysis 
Statistical analyses employed are indicated in the figure captions. Unless otherwise stated, data are 
expressed as means ± standard deviation. Statistical analyses employed included the two-tailed Student T-
test, One-way ANOVA and Two-way ANOVA (using GraphPad Prism 6 software), where a P value of > 
0.05 was not considered significant. Whether the data followed a sigmoidal dose response curve was 
assessed using GraphPad Prism 6 software, using the equation  Y=B+(T-B)*Xn/(Kan+Xn), where B and T 
correspond to bottom and top plateau intensities, respectively, Ka is the concentration that induces the 50% 
response, and X and Ka values are raised to the nth power. 
Supporting Information 
This Supporting Information is available free of charge via the Internet at http://pubs.acs.org.  
It includes details of theoretical modeling of USSN, IL-ȕSURGXFWLRQLQ3%0&FXOWXUHVWUHDWHGZLWK/36
and USSN or peptidoglycan, USSN dissolution in cell culture media (0-8 h), cell distribution in monocyte-
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deplete PBMC cultures, gating strategies used in flow cytometric analyses, zeta-potential of USSN in RPMI 
and PBS, gene pathways significantly up or down-regulated in PBMC after USSN treatment.  
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